title: Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries.
abstract: OBJECTIVE
  To assess human papillomavirus (HPV) vaccination coverage after demonstration projects conducted in India, Peru, Uganda and Viet Nam by PATH and national governments and to explore the reasons for vaccine acceptance or refusal.
  
  
  METHODS
  Vaccines were delivered through schools or health centres or in combination with other health interventions, and either monthly or through campaigns at fixed time points. Using a two-stage cluster sample design, the authors selected households in demonstration project areas and interviewed over 7000 parents or guardians of adolescent girls to assess coverage and acceptability. They defined full vaccination as the receipt of all three vaccine doses and used an open-ended question to explore acceptability.
  
  
  RESULTS
  Vaccination coverage in school-based programmes was 82.6% (95% confidence interval, CI: 79.3-85.6) in Peru, 88.9% (95% CI: 84.7-92.4) in 2009 in Uganda and 96.1% (95% CI: 93.0-97.8) in 2009 in Viet Nam. In India, a campaign approach achieved 77.2% (95% CI: 72.4-81.6) to 87.8% (95% CI: 84.3-91.3) coverage, whereas monthly delivery achieved 68.4% (95% CI: 63.4-73.4) to 83.3% (95% CI: 79.3-87.3) coverage. More than two thirds of respondents gave as reasons for accepting the HPV vaccine that: (i) it protects against cervical cancer; (ii) it prevents disease, or (iii) vaccines are good. Refusal was more often driven by programmatic considerations (e.g. school absenteeism) than by opposition to the vaccine.
  
  
  CONCLUSIONS
  High coverage with HPV vaccine among young adolescent girls was achieved through various delivery strategies in the developing countries studied. Reinforcing positive motivators for vaccine acceptance is likely to facilitate uptake.
authors.affiliation: PATH, PO Box 900922, Seattle, WA, 98109, United States of America. slamontagne@path.org
authors.forename: D Scott
authors.initials: DS
authors.lastname: LaMontagne
authors.forename: Sandhya
authors.initials: S
authors.lastname: Barge
authors.forename: Nga Thi
authors.initials: NT
authors.lastname: Le
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mugisha
authors.forename: Mary E
authors.initials: ME
authors.lastname: Penny
authors.forename: Sanjay
authors.initials: S
authors.lastname: Gandhi
authors.forename: Amynah
authors.initials: A
authors.lastname: Janmohamed
authors.forename: Edward
authors.initials: E
authors.lastname: Kumakech
authors.forename: N Rocio
authors.initials: NR
authors.lastname: Mosqueira
authors.forename: Nghi Quy
authors.initials: NQ
authors.lastname: Nguyen
authors.forename: Proma
authors.initials: P
authors.lastname: Paul
authors.forename: Yuxiao
authors.initials: Y
authors.lastname: Tang
authors.forename: Tran Hung
authors.initials: TH
authors.lastname: Minh
authors.forename: Bella Patel
authors.initials: BP
authors.lastname: Uttekar
authors.forename: Aisha O
authors.initials: AO
authors.lastname: Jumaan
mesh_terms: D000293:Adolescent; D002648:Child; D016000:Cluster Analysis; D016001:Confidence Intervals; D003430:Cross-Sectional Studies; D003906:Developing Countries / Q000706:statistics & numerical data*; D005260:Female; D014943:Global Health; D019538:Health Care Surveys; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data*; D007182:Income; D007194:India; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D010568:Peru; D011203:Poverty / Q000706:statistics & numerical data; D016730:Program Development; D015397:Program Evaluation; D012959:Socioeconomic Factors; D014454:Uganda; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control; D014744:Vietnam; D016387:Women's Health
chemical_list: D053918:Papillomavirus Vaccines
references.citation: Vaccine. 2010 Jul 12;28(31):4864-7
references.pmid: 20566394
references.citation: Vaccine. 2008 Aug 5;26(33):4120-34
references.pmid: 18617295
references.citation: Salud Publica Mex. 2010 May-Jun;52(3):226-33
references.pmid: 20485886
references.citation: J Low Genit Tract Dis. 2010 Jul;14(3):179-84
references.pmid: 20592552
references.citation: Immunotherapy. 2009 Sep;1(5):795-807
references.pmid: 20636024
references.citation: Vaccine. 2008 May 23;26(22):2669-79
references.pmid: 18455843
references.citation: MMWR Morb Mortal Wkly Rep. 2010 Aug 20;59(32):1018-23
references.pmid: 20724968
references.citation: BMJ. 2008 May 10;336(7652):1056-8
references.pmid: 18436917
references.citation: Vaccine. 2011 Jul 12;29(31):5022-30
references.pmid: 21609748
references.citation: PLoS Med. 2010 May 04;7(5):e1000270
references.pmid: 20454567
references.citation: Lancet. 2008 Dec 13;372(9655):2031-46
references.pmid: 19070738
references.citation: Pharmacoeconomics. 2005;23(11):1107-22
references.pmid: 16277547
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/201-9
references.pmid: 16950008
references.citation: Eur J Obstet Gynecol Reprod Biol. 2007 Jan;130(1):25-9
references.pmid: 16973254
references.citation: Arch Pediatr Adolesc Med. 2005 Feb;159(2):132-7
references.pmid: 15699306
references.citation: Aust N Z J Public Health. 2009 Aug;33(4):365-70
references.pmid: 19689598
references.citation: Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):645-50
references.pmid: 19827887
references.citation: Sex Health. 2010 Sep;7(3):262-70
references.pmid: 20719213
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Vaccine. 2008 Jul 29;26(32):4080-93
references.pmid: 18550229
references.citation: MMWR Morb Mortal Wkly Rep. 2010 Oct 29;59(42):1367-71
references.pmid: 21030941
references.citation: Wkly Epidemiol Rec. 2009 Apr 10;84(15):118-31
references.pmid: 19360985
references.citation: Bull World Health Organ. 2008 Jun;86(6):488-90
references.pmid: 18568279
references.citation: Indian J Med Res. 2009 Sep;130(3):327-33
references.pmid: 19901442
references.citation: Vaccine. 2009 Aug 20;27(38):5203-8
references.pmid: 19596420
references.citation: Vaccine. 2010 May 28;28(24):4027-37
references.pmid: 20412875
references.citation: J Womens Health (Larchmt). 2009 Feb;18(2):225-33
references.pmid: 19183094
references.citation: Afr J Reprod Health. 2008 Dec;12(3):159-72
references.pmid: 19435020
references.citation: Eur J Obstet Gynecol Reprod Biol. 2008 Mar;137(1):103-7
references.pmid: 17368910
references.citation: Curr Med Res Opin. 2006 Apr;22(4):663-70
references.pmid: 16684427